Haemonetics Stock Today
| HAE Stock | USD 83.46 1.42 1.67% |
Performance1 of 100
| Odds Of DistressLess than 1
|
Haemonetics is trading at 83.46 as of the 18th of April 2024, a -1.67% down since the beginning of the trading day. The stock's lowest day price was 82.89. Haemonetics has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Haemonetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 9th of May 1991 | Category Healthcare | Classification Health Care |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. The company has 50.79 M outstanding shares of which 2.04 M shares are currently shorted by investors with about 4.36 days to cover. More on Haemonetics
Moving against Haemonetics Stock
| 0.48 | AHG | Akso Health Group | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
Haemonetics Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Haemonetics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Haemonetics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Christopher Simon | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [HAEMATO, HAEMATO, HAEMATO AG, HAEMATO AG] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, SP Midcap 400, Baby Boomer Prospects, Medical Equipment, Obamacare Repeal, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Haemonetics report their recommendations after researching Haemonetics' financial statements, talking to executives and customers, or listening in on Haemonetics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Haemonetics. The Haemonetics consensus assessment is calculated by taking the average forecast from all of the analysts covering Haemonetics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Haemonetics' liquidity, profitability, solvency, and operating efficiency, Haemonetics is performing exceptionally good at this time. It has a great probability to report excellent financial results in May. Financial strength of Haemonetics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haemonetics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Haemonetics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Haemonetics' financial leverage. It provides some insight into what part of Haemonetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haemonetics (HAE) is traded on New York Stock Exchange in USA. It is located in 125 Summer Street, Boston, MA, United States, 02110 and employs 3,034 people. Haemonetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 4.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Haemonetics's market, we take the total number of its shares issued and multiply it by Haemonetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Haemonetics runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 50.79 M outstanding shares of which 2.04 M shares are currently shorted by investors with about 4.36 days to cover.
Haemonetics has about 284.47 M in cash with 273.06 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.79.
Check Haemonetics Probability Of Bankruptcy
Ownership AllocationHaemonetics secures a total of 50.79 Million outstanding shares. The majority of Haemonetics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Haemonetics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Haemonetics. Please pay attention to any change in the institutional holdings of Haemonetics as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Haemonetics Ownership Details
Haemonetics Stock Price Odds Analysis
What are Haemonetics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Haemonetics jumping above the current price in 90 days from now is about 17.94%. The Haemonetics probability density function shows the probability of Haemonetics stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.2565. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Haemonetics will likely underperform. Additionally, haemonetics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Haemonetics to move above the current price in 90 days from now is about 17.94 (This Haemonetics probability density function shows the probability of Haemonetics Stock to fall within a particular range of prices over 90 days) .
Haemonetics Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Haemonetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Haemonetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Haemonetics' value.| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 826.7 K | |
| Btim Corp | 2023-12-31 | 716.5 K | |
| Amvescap Plc. | 2023-12-31 | 715.9 K | |
| Westfield Capital Management Company, Lp | 2023-12-31 | 712.1 K | |
| Fisher Asset Management, Llc | 2023-12-31 | 711.7 K | |
| Boston Partners Global Investors, Inc | 2023-12-31 | 707.4 K | |
| Schroder Investment Management Group | 2023-12-31 | 656.8 K | |
| Northern Trust Corp | 2023-12-31 | 628.5 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 534.7 K | |
| Capital Research Global Investors | 2023-12-31 | 6.5 M | |
| Blackrock Inc | 2023-12-31 | 6 M |
Haemonetics Historical Income Statement
Haemonetics Income Statement is one of the three primary financial statements used for reporting Haemonetics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Haemonetics revenue and expense. Haemonetics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Haemonetics' Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 188.4 M, whereas Cost Of Revenue is forecasted to decline to about 318.9 M. View More FundamentalsHaemonetics Stock Against Markets
Picking the right benchmark for Haemonetics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Haemonetics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Haemonetics is critical whether you are bullish or bearish towards Haemonetics at a given time. Please also check how Haemonetics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Haemonetics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Haemonetics Corporate Directors
Haemonetics corporate directors refer to members of a Haemonetics board of directors. The board of directors generally takes responsibility for the Haemonetics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Haemonetics' board members must vote for the resolution. The Haemonetics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Susan Foote | Independent Director | Profile | |
| Robert Abernathy | Independent Director | Profile | |
| Claire Pomeroy | Independent Director | Profile | |
| Catherine Burzik | Independent Director | Profile |
How to buy Haemonetics Stock?
Before investing in Haemonetics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Haemonetics. To buy Haemonetics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Haemonetics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Haemonetics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Haemonetics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Haemonetics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Haemonetics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Haemonetics Stock please use our How to Invest in Haemonetics guide.
Already Invested in Haemonetics?
The danger of trading Haemonetics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Haemonetics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Haemonetics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Haemonetics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 2.46 | Revenue Per Share 25.092 | Quarterly Revenue Growth 0.101 | Return On Assets 0.0612 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.